Sofosbuvir and Velpatasvir With or Without Voxilaprevir in Direct-Acting Antiviral-Naïve Chronic Hepatitis C: Patient-Reported Outcomes From POLARIS 2 and 3

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14423
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus

Hepatology
MedicineHepatology
2017English

Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia

American Journal of Hematology
Hematology
2018English

Oral Direct-Acting Antiviral Therapy for Hepatitis C

Journal of Antivirals & Antiretrovirals
2012English

Clinical Outcomes of Direct-Acting Antiviral Therapy in Patients With Compensated Hepatitis C Virus-Related Cirrhosis

Hepatoma Research
2017English

Generic Sofosbuvir-Based Interferon-Free Direct Acting Antiviral Agents for Patients With Chronic Hepatitis C Virus Infection: A Real-World Multicenter Observational Study

Scientific Reports
Multidisciplinary
2018English

Treatment of the Chronic Hepatitis C Complicated by Mixed Cryoglobulinemia With Direct-Acting Antiviral Agents

Jurnal Infektologii
Infectious Diseases
2018English

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Gastroenterology
HepatologyGastroenterology
2016English

Direct-Acting Antiviral Drugs and Hepatitis C Virus: A Therapeutic Revolution?

Cancer
Cancer ResearchOncology
2015English

Make Platelet Count Great Again: Direct‐acting Antiviral Agent Therapy in Patients With Chronic Hepatitis C

Advances in Digestive Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy